Dr. Suzanne Cole

Hematology
3030 Waterview Pkwy, 
Richardson, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
3030 Waterview Pkwy, 
Richardson, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suzanne Cole is a Hematologist in Richardson, Texas. Dr. Cole is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Non-Muscle Invasive Bladder Cancer, Thrombectomy, and Nephrectomy.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
3030 Waterview Pkwy, Richardson, TX 75080

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Early Phase 1
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (CIRTiN-BC): A Phase II, Single-Arm Trial
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (CIRTiN-BC): A Phase II, Single-Arm Trial
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

32 Total Publications

Innate and adaptive immune features associated with immune-related adverse events.
Innate and adaptive immune features associated with immune-related adverse events.
Journal: Journal for immunotherapy of cancer
Published: July 30, 2025
Similar Doctors
Elite in Renal Cell Carcinoma (RCC)
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology
Elite in Renal Cell Carcinoma (RCC)
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (13.1 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Brugarolas is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Brugarolas is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Advanced in Renal Cell Carcinoma (RCC)
Dr. Jue Wang
Oncology | Hematology Oncology | Hematology
Advanced in Renal Cell Carcinoma (RCC)
Dr. Jue Wang
Oncology | Hematology Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (13.1 miles away)
214-648-7740
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jue Wang is an Oncologist and a Hematologist Oncology provider in Dallas, Texas. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Wilms Tumor, and WT1-Related Wilms Tumor Syndromes.

Advanced in Renal Cell Carcinoma (RCC)
Dr. Mary U. Milam
Hematology Oncology | Oncology | Hematology
Advanced in Renal Cell Carcinoma (RCC)
Dr. Mary U. Milam
Hematology Oncology | Oncology | Hematology
1307 8th Ave, Suite 205, 
Fort Worth, TX 
 (38.7 miles away)
817-924-4300
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary Milam is a Hematologist Oncology specialist and an Oncologist in Fort Worth, Texas. Dr. Milam is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Pleuropulmonary Blastoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bone Marrow Aspiration, and Ureteroscopy. Dr. Milam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cole's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile